用热点引导的生成深度学习来设计类似药物的PPI抑制剂
Heqi Sun1, Jiayi Li1,2, Yufang Zhang3,4
1State Key Laboratory of Microbial Metabolism, Shanghai-Islamabad-Belgrade Joint Innovation Center on Antibacterial Resistances, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Hot2Mol是一个新的深度学习框架,设计针对蛋白质与蛋白质相互作用 (PPI) 的小分子抑制剂. 这种方法通过产生独特,强效和类似药物的化合物来加速药物发现,
科学领域:
- 计算化学
- 药物发现
- 医学中的人工智能
背景情况:
- 蛋白与蛋白相互作用 (PPI) 是关键的治疗点.
- 开发PPI的小分子抑制剂是具有挑战性的,因为它们的接口很大,很平.
- 现有的计算方法受限于化学库和启发式,限制了新药设计.
研究的目的:
- 推出Hot2Mol,一个用于PPI抑制剂新设计的生成深度学习框架.
- 通过使用热点残留物的药用特征来准确地定位PPI接口.
- 克服传统方法的局限性,探索药物发现的新化学空间.
主要方法:
- Hot2Mol集成了一个条件变压器,用于制约性质的分子生成.
- 一个E{n}等同的图形神经网络确保了与PPI热点药源的空间对齐.
- 变化自编码器用于采样多样化和新型分子结构.
主要成果:
- Hot2Mol在结合亲和力,药物相似性和新奇性方面超过了最先进的模型.
- 产生的化合物具有强大的结合稳定性,由分子动力学模拟证实.
- 案例研究证明了高亲和性和选择性PPI抑制剂的设计.
结论:
- Hot2Mol有效地设计了针对特定的和类似药物的PPI抑制剂.
- 这一框架加速了对具有挑战性的PPI目标的合理药物发现.
- Hot2Mol代表了PPI计算药物设计的重大进步.
更多相关视频
06:50Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
相关概念视频
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Protein-protein Interfaces
